Search

Your search keyword '"Lebbé, Céleste"' showing total 166 results

Search Constraints

Start Over You searched for: Author "Lebbé, Céleste" Remove constraint Author: "Lebbé, Céleste" Database ScienceDirect Remove constraint Database: ScienceDirect
166 results on '"Lebbé, Céleste"'

Search Results

1. When to stop immunotherapy for advanced melanoma: the emulated target trials

2. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy

3. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024

4. Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma

5. Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database

8. Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.

9. Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy

10. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

11. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects

12. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

13. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023

14. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023

18. Characteristics of circulating KSHV-infected viroblasts during active KSHV+ multicentric Castleman disease

20. Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort

21. CLAUDIUS Study: Risk of materno-fetal transmission of melanoma cells in pregnant women with high grade melanoma – A retrospective multicenter study and literature review

22. Immune-related generalised oedema – A new category of adverse events with immune checkpoint inhibitors

23. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial

24. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases

25. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022

26. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022

27. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022

29. Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort

30. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

31. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis

33. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

34. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

35. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

36. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response

37. Hematological immune related adverse events after treatment with immune checkpoint inhibitors

41. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention

42. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment

44. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019

45. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019

46. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials

48. Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study

49. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

Catalog

Books, media, physical & digital resources